Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Chiara ZeccaFrancesca BovisGiovanni NoviMarco CapobiancoRoberta LanzilloJessica FrauAnna Maria RepiceBahia HakikiSabrina RealmutoSimona BonavitaErica CurtiLaura BrambillaGiorgia MataluniPaola CavallaAlessia Di SapioElisabetta SignorielloStefania BaroneGiorgia T ManiscalcoIlaria MaiettaIsabella MaraffiGiacomo BoffaSimona MalucchiAgostino NozzolilloGiancarlo CogheClaudia MechiGiuseppe SalemiAntonio GalloRosaria SaccoMaria CellerinoMaria MalentacchiMarcello De AngelisLorena LoreficeEliana MagnaniElio PrestipinoFrancesca SperliVincenzo Brescia MorraGiuseppe FenuAlessandro BarilaroGianmarco AbbadessaAlessio SignoriFranco GranellaMaria Pia AmatoAntonio UccelliClaudio GobbiMaria Pia SormaniPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)
Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.
Keyphrases
- disease activity
- multiple sclerosis
- systemic lupus erythematosus
- rheumatoid arthritis
- diffuse large b cell lymphoma
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- randomized controlled trial
- mass spectrometry
- systematic review
- hodgkin lymphoma
- chronic lymphocytic leukemia
- ms ms
- machine learning
- deep learning